These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22017590)

  • 1. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
    Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
    Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
    Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
    Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
    Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
    Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
    Naumovski L; Junutula JR
    Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
    Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
    J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions.
    Zhuo H; Zhou L
    Pharmazie; 2016 Oct; 71(10):555-561. PubMed ID: 29441921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
    Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
    J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate.
    Qian X; Mills E; Torgov M; LaRochelle WJ; Jeffers M
    Mol Oncol; 2008 Jun; 2(1):81-93. PubMed ID: 19383330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cripto monoclonal antibodies.
    Hu XF; Xing PX
    Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of the glycoprotein osteoactivin/glycoprotein nonmetastatic melanoma protein B in pancreatic cancer.
    Torres C; Linares A; Alejandre MJ; Palomino-Morales R; Martin M; Delgado JR; Martinez J; Perales S
    Pancreas; 2015 Mar; 44(2):302-10. PubMed ID: 25426614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
    Pollack VA; Alvarez E; Tse KF; Torgov MY; Xie S; Shenoy SG; MacDougall JR; Arrol S; Zhong H; Gerwien RW; Hahne WF; Senter PD; Jeffers ME; Lichenstein HS; LaRochelle WJ
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):423-35. PubMed ID: 17541593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
    Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).
    Vaklavas C; Forero A
    BioDrugs; 2014 Jun; 28(3):253-63. PubMed ID: 24496926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.
    Rose AA; Annis MG; Dong Z; Pepin F; Hallett M; Park M; Siegel PM
    PLoS One; 2010 Aug; 5(8):e12093. PubMed ID: 20711474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.
    Rose AAN; Biondini M; Curiel R; Siegel PM
    Pharmacol Ther; 2017 Nov; 179():127-141. PubMed ID: 28546082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
    Keir CH; Vahdat LT
    Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells.
    Oyewumi MO; Manickavasagam D; Novak K; Wehrung D; Paulic N; Moussa FM; Sondag GR; Safadi FF
    Oncotarget; 2016 Mar; 7(12):13932-44. PubMed ID: 26883195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPNMB expression in uveal melanoma: a potential for targeted therapy.
    Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
    Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cripto: a novel target for antibody-based cancer immunotherapy.
    Xing PX; Hu XF; Pietersz GA; Hosick HL; McKenzie IF
    Cancer Res; 2004 Jun; 64(11):4018-23. PubMed ID: 15173016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cancer immunotherapy: recent breakthroughs and perspectives].
    Tartour E; Sandoval F; Bonnefoy JY; Fridman WH
    Med Sci (Paris); 2011 Oct; 27(10):833-41. PubMed ID: 22027420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.